| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
3',4'-Dihydroxyflavonol targets oxidative stress pathways as an effective antioxidant. It reduces superoxide production and improves nitric oxide (NO) function in diabetic rat mesenteric arteries. The compound is a neuroprotective agent. Its mechanism involves scavenging free radicals and modulating NO signaling pathways. 3',4'-Dihydroxyflavonol has potential applications in cardiovascular and neurological research.
|
|---|---|
| ln Vitro |
In the presence of elevated reactive oxygen species (ROS), 3',4'-Dihydroxyflavonol (DiOHF) acutely preserves nitric oxide (NO) activity. DiOHF enhances endothelial function by inhibiting eNOS uncoupling and lowering Nox2-dependent superoxide production, which raises NO activity in diabetics [1]. In permeabilized tertiary branches of rat mesenteric arteries, 3',4'-Dihydroxyflavonol decreases vasoconstriction by Ca2+ desensitization [2].
In vitro, 3',4'-Dihydroxyflavonol is an effective antioxidant that reduces superoxide and improves nitric oxide (NO) function. It is a neuroprotective agent. The compound is a hydroxyflavan. Its antioxidant activity has been characterized in various cell-free and cell-based assays. The compound reduces superoxide production in vascular tissues. Its neuroprotective effects have been demonstrated in neuronal cell models. |
| ln Vivo |
In vivo, 3',4'-Dihydroxyflavonol reduces superoxide and improves nitric oxide (NO) function in diabetic rat mesenteric arteries. It is a neuroprotective agent. The compound has potential applications in cardiovascular and neurological research. Further in vivo studies are needed to fully characterize its therapeutic potential for diabetic complications and neurodegenerative diseases.
|
| Enzyme Assay |
In vitro antioxidant assays for 3',4'-Dihydroxyflavonol involve measuring superoxide scavenging activity and nitric oxide production. Superoxide levels are measured using chemiluminescence or fluorescent probes. Nitric oxide production is measured using Griess reagent or fluorescent NO indicators. The compound is added at varying concentrations, and IC50 values are calculated from dose-response curves. Neuroprotective effects are assessed in neuronal cell models exposed to oxidative stress. Assays are performed in appropriate buffer systems with positive controls.
|
| Cell Assay |
In vitro cell-based assays for 3',4'-Dihydroxyflavonol are conducted in vascular smooth muscle cells, neuronal cells, and other relevant cell types. Cells are cultured in appropriate media at 37°C with 5% CO2 and treated with the compound at varying concentrations. Superoxide production is measured using fluorescent probes. Nitric oxide production is measured using Griess reagent or fluorescent indicators. Cell viability is assessed by standard assays. Neuroprotection is assessed in models of oxidative stress or excitotoxicity. Experiments are performed in triplicate with appropriate positive and negative controls.
|
| Animal Protocol |
3',4'-Dihydroxyflavonol in vivo studies are conducted in animal models of diabetes and neurodegeneration. Animals are treated with the compound via oral administration or injection. For diabetic studies, mesenteric arteries are isolated and superoxide production and NO function are assessed. For neuroprotection studies, animal models of neurodegeneration are used. Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological and biomarker analysis at study endpoints. Studies are conducted in accordance with institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Known metabolites of 3,3p,4p-trihydroxyflavonoids include (2S,3S,4S,5R)-6-[2-(3,4-dihydroxyphenyl)-4-oxochromen-3-yl]oxy-3,4,5-trihydroxyoxacyclohexane-2-carboxylic acid. 3',4'-Dihydroxyflavonol (MW 270.24 g/mol, C15H10O5) is a hydroxyflavan and neuroprotective agent. It is also known as 3,3',4'-trihydroxyflavone and DiOHF. The compound is soluble in organic solvents. It is stable under recommended storage conditions. 3',4'-Dihydroxyflavonol is used in antioxidant and neuroprotection research. Pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution would be determined in species-specific studies. |
| Toxicity/Toxicokinetics |
3',4'-Dihydroxyflavonol is generally well-tolerated in preclinical studies. The compound is a natural flavonoid with established safety profiles. Its antioxidant and neuroprotective effects have been demonstrated with acceptable safety profiles. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| References |
|
| Additional Infomation |
3,3',4'-Trihydroxyflavonoids are hydroxyflavones.
3',4'-Dihydroxyflavonol (DiOHF, 3,3',4'-trihydroxyflavone) is an effective antioxidant that reduces superoxide and improves nitric oxide (NO) function in diabetic rat mesenteric arteries. It is a neuroprotective agent. The compound has potential applications in cardiovascular and neurological research. Its molecular formula is C15H10O5 with a molecular weight of 270.24 g/mol. All applications are limited to non-human research use. |
| Molecular Formula |
C15H10O5
|
|---|---|
| Molecular Weight |
270.2369
|
| Exact Mass |
270.053
|
| CAS # |
6068-78-6
|
| PubChem CID |
145826
|
| Appearance |
Yellow to green solid powder
|
| Density |
1.579g/cm3
|
| Boiling Point |
508.9ºC at 760 mmHg
|
| Flash Point |
198ºC
|
| Index of Refraction |
1.747
|
| LogP |
2.576
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
20
|
| Complexity |
430
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
KPGMHZQXQVDYNT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H10O5/c16-10-6-5-8(7-11(10)17)15-14(19)13(18)9-3-1-2-4-12(9)20-15/h1-7,16-17,19H
|
| Chemical Name |
2-(3,4-dihydroxyphenyl)-3-hydroxychromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~462.55 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7004 mL | 18.5021 mL | 37.0041 mL | |
| 5 mM | 0.7401 mL | 3.7004 mL | 7.4008 mL | |
| 10 mM | 0.3700 mL | 1.8502 mL | 3.7004 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
